1Sylvester R J, Van der Meijden PM, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stages TaT1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC TriMs [ J ]. Eur Urol, 2006,49 ( 3 ) :466-477.
2Van Rhijn BWG, Burger M, Lotan Y, et al. Recurrence and Progression of Disease in Non-Muscle-Invasive Bladder Cancer:From Epidemiology to Treatment Strategy [ J ]. Eur Urol, 2009,56 ( 3 ) : 430442.
4Spiess PE, Grossman HB. Fluorescence cystoscopy : is it ready for use in routine clinical practice? [J]. Curr Opin Urol,2006, 16 (5) :372-376.
5Jain S, Kockelbergh RC. The role of photodynamic diagnosis in the contemporary management of superficial bladder cancer[ J ]. BJU Int,2005,96( 1 ) : 17-21.
6Sim HG, Lau WKO, Olivo M ,et al. Is photodynamic diagnosis using hypericin better than white-light cystoscopy for detecting superficial bladder carcinoma? [J]. BJU Int,2005,95(9) :1215-1218.
7Hungerhuber E, Stepp H, Kriegmair M, et al. Seven years' experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder[ J]. Urology,2007,69(2) :260-264.
8Kubin A, Meissner P, Wierrani F, et al. Fluorescence diagnosis of bladder cancer with new water soluble hypericin bound to polyvinylpyrrolidone : PVP-hypericin [ J ]. Photochem Photobiol, 2008,84 (6) :1560-1563.
9Jichlinski P, Guillou L, Karlsen SJ, et al. Hexyl aminolevulinate fluorescence cystoscopy:new diagnostic tool for superficial bladder cancer-amulticenter study [ J ]. J Urol,2003,170 ( 1 ) : 226 -229.
